2区 · 医学
Article
作者: Kildahl-Andersen, Geir ; Heikal, Adam ; Skagseth, Susann ; Fröhlich, Christopher ; Andresen, Adriana Magalhaes Santos ; Rongved, Pål ; Økstad, Ole Andreas ; Bayer, Annette ; Leiros, Hanna-Kirsti S. ; Lauksund, Silje ; Carlsen, Trine Josefine Olsen ; Huber, Sandra ; Gjøen, Tor ; Finke, Sarah ; Åstrand, Ove Alexander Høgmoen ; Samuelsen, Ørjan ; Schnaars, Christian
Carbapenem-resistant Gram-negative pathogens are a critical public health threat and there is an urgent need for new treatments. Carbapenemases (β-lactamases able to inactivate carbapenems) have been identified in both serine β-lactamase (SBL) and metallo-β-lactamase (MBL) families. The recent introduction of SBL carbapenemase inhibitors has provided alternative therapeutic options. Unfortunately, there are no approved inhibitors of MBL-mediated carbapenem-resistance and treatment options for infections caused by MBL-producing Gram-negatives are limited.